The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The FDA has expanded the approval of an intravenous injection for the treatment of metastatic or unresectable melanoma to include use in pediatric patients.
The first-and-only fully human monoclonal anti-epidermal growth factor receptor antibody for the treatment of wild-type RAS metastatic colorectal cancer was recently approved by the US Food and Drug...
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
